wu hepingfor china daili enterpris suppli vaccin vital medic resourc worldwid may 12 chines biopharmaceut compani sinovac biotech began build vaccin factori quilicura chile design annual product capac 50 million dose flavio salazar south american nation minist scienc technolog knowledg innov said launch ceremoni factori project strateg import develop chile vaccin manufactur industri halt develop 20 year cover 21000 squar meter factori produc packag vaccin design protect diseas includ covid19 hepat flu also aim enhanc product local vaccin date 26 million dose compani covid19 vaccin administ chile three day factori ceremoni sinovac biotech award ministri stateown enterpris indonesia cooper covid19 control measur compani southeast asian countri sinovac biotech provid 280 million dose covid19 vaccin indonesia 100 million export semifinish product packag local soe bio pharm sinovac partner joint manufactur coronaviru vaccin two latest exampl numer contribut made chines compani global fight pandem recognit govern public oversea sinc pandem began chines compani provid mani nation vaccin develop quickli along key medic resourc test kit protect cloth emerg rapidlyspread highli transmiss omicron variant covid19 chines enterpris expect continu play import role fight diseas claim million live worldwid sever impact global economi may 22 world health organ warn pandem continu even mani countri lift restrict aim stop spread covid19 6 million death diseas report organ latest estim show number fatal much higher nearli 15 million global flow foreign direct invest vital sustain develop poorer area world also hit pandem caus widespread concern amid uncertainti geopolit issu beij chen jia research renmin univers china intern monetari institut said solut chines enterpris expect help world strengthen defens pandem especi emerg new variant global industri suppli chain heavi pressur chines pharmaceut enterpris becom major forc china help world narrow vaccin divideth inequit alloc covid19 vaccin chen said enterpris constantli optim research develop new product better deal mutat viru make contribut contain pandem global nurs hold syring contain covid19 vaccin made beij institut biolog product unit sinopharm subsidiari china nation biotec group cnbg vaccin center beij april 15 2021 photoag new growth analyst said thank dilig effort pursu highqual develop recent year chines compani produc pharmaceut medic devic embark fresh growth path featur new product research develop base innov clinic valu progress fuel develop pharmaceut healthcar industri china also promis effect way world contain least cope constantli evolv coronaviru may 23 shanghai junshi bioscienc co said oral anticovid19 drug develop met primari goal phase3 clinic studi earli treatment mild moder case diseas shanghai compani said would soon contact domest health author regist drug jointli develop sever domest entiti includ vigonvita life scienc co three affili chines academi scienc phase2 clinic trial drug complet uzbekistan last year among patient moder sever covid19 found two differ dose drug favor safeti efficaci treat patient comparison standard therapi base posit result drug design inhibit replic coronaviru approv treat moder sever case covid19 central asian nation april kintor pharma clinicalstag biotechnolog compani suzhou jiangsu provinc said potenti covid19 treatment significantli reduc hospit death covid19 outpati phase3 multiregion clinic trial especi among middleag elderli patient highrisk factor compani expand product capac drug 50 million dose end year said statement meanwhil china nation biotec group subsidiari china nation pharmaceut group also known sinopharm develop three omicron vaccin begin clinic trial earli last month sinovac biotech also obtain approv clinic trial omicron vaccin chines mainland hong kong jiangsu recbio technolog co innov vaccin compani found 2012 taizhou jiangsu develop world first lyophil freezedri omicronspecif mrna vaccin store transport temperatur 2 8 mrna vaccin teach immun system make memori cell even though candid vaccin preclin studi stage success complet studi trial success launch market expect significantli improv access vaccin requir ultracold storag transport condit unlik alreadi market staff member sinovac work covid19 vaccin product line beij juli 8 2021 photoxinhua great progress liu yong founder chairman jiangsu recbio technolog said research develop rd product commerci chines pharmaceut industri made remark progress recent year thank support regulatori environ polici measur attract highend oversea talent enabl hightech enterpris expand financ also provid strong support domest pharmaceut enterpris grow data china intern develop cooper agenc show nation provid 2 billion dose covid19 vaccin total 120 countri intern organ china also transfer vaccin manufactur technolog 20 nation result oversea annual vaccin product capac 1 billion dose sinovac biotech grant access licens 60 countri intern organ region total covid19 vaccin coronavac suppli 28 billion dose worldwid compani also plan establish vaccin factori least 10 countri includ egypt south africa chile indonesia strengthen intern cooper help egypt build fulli autom cold storag facil accommod 150 million dose vaccin complet facil largest vaccin storag center africa greatli improv cold chain storag contin sinovac biotech help construct bric vaccin research develop center branch china also cooper univers research institut industri bric nation brazil russia india china south africa countri gao qiang compani chief oper offic said order play better role global pharmaceut industri chines enterpris must advanc innovationdriven develop strengthen global cooper sinopharm group stateown pharmaceut compani produc nearli 100 vaccin product 200 bioproduct spent 20 billion yuan 3 billion scientif research 13th fiveyear plan period 201620 compani increas invest rd one worldwid independ develop vaccin also test kit treatment diseas produc four covid19 test kit four antiviru therapi four titl vaccin potenti vaccin total 119 countri region intern organ approv use covid19 vaccin made sinopharm subsidiari cnbg produc 3 billion dose vaccin home oversea sinopharm chairman liu jingzhen said approv use larg number countri region covid19 vaccin wide use world largest inocul popul best safeti record effici product capac proud contribut global contain diseas increas worldwid presenc pharmaceut product develop china shi lichen founder medic consult compani beij dingchen consult also spoke highli contribut global antipandem effort made chines enterpris manufactur medic devic especi omicron variant increas demand rapid conveni test thank solid manufactur capac impress effici organ develop product urgent need product chines produc make covid19 test kit larg scale meet demand home abroad shi said model bgi genom huoyan air laboratori showcas china pavilion dubai world expo dubai jan 11 2022 photo provid chinadailycomcn rang test shenzhen guangdong provinc bgi genom one world largest genom sequenc compani develop varieti covid19 test use variou technolog meet diversifi demand test product export total 180 countri region compani covid19 rapid nucleic acid test kit sensit mani antigen detect product suitabl selfus meet demand rapid test frontlin situat custom control point airport port lack profession laboratori facil personnel bgi came solut call pm easi laban integr system detect eight common respiratori pathogen simultan includ covid19 accord shi vitro diagnost devic ivd design examin sampl taken bodi requir larg amount knowledg interdisciplinari research develop along manufactur laboratori applic involv biolog physic chemistri optoelectron genet extrem difficult develop highend ivd shi ad effort chines ivd produc meet increas demand pandem seen climb industri valu chain becom better prepar develop topqual origin product highend market ad howev expert said chines pharmaceut medic devic compani need make effort strengthen rd innov capabl ventur deeper global market especi develop economi meng lilian chief analyst sichuan tianfu health industri research institut chengdu capit sichuan provinc said factor prevent compani expand presenc oversea includ low accept chinamad drug develop market ineffici commerci tradit chines medicin tcm oversea chen research renmin univers said chines enterpris must becom alert variat regulatori environ differ countri also reinforc rd innov capabl best way increas global presenc continu improv product servic qualiti said tcm expect win increas global accept intern cooper product rd enhanc chen ad global export covid19 vaccin declin chines produc also expect strengthen technolog manufactur cooper foreign counterpart invest rd chen said